The Journal of the American Dental Association
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Am Dent Assoc, Vol 137, No 11, 1562-1571.
© 2006 American Dental Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hersh, E. V.
Right arrow Articles by Townsend, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hersh, E. V.
Right arrow Articles by Townsend, R. R.
Related Collections
Right arrow Pharmacology

RESEARCH

The pharmacokinetics and cardiovascular effects of high-dose articaine with 1:100,000 and 1:200,000 epinephrine



Elliot V. Hersh, DMD, MS, PhD, Helen Giannakopoulos, DMD, MD, Lawrence M. Levin, DMD, MD, Stacey Secreto, Paul A. Moore, DMD, PhD, MPH, Carrie Peterson, BS, Matthew Hutcheson, MS, Mohammed Bouhajib, MS, Ari Mosenkis, MD and Raymond R. Townsend, MD

Objectives. The authors conducted a randomized, double-blind, two-way crossover clinical trial to compare the pharmacokinetics and cardiovascular effects of 11.9 milliliters of 4 percent articaine hydrochloride (HCl) plus 1:100,000 epinephrine (A100) with those of 11.9 mL of 4 percent articaine HCl plus 1:200,000 epinephrine (A200).

Methods. During two testing sessions, the authors administered injections of A100 and A200 over a seven-minute period (in one-cartridge doses unless otherwise noted): maxillary right first molar infiltration, maxillary left first molar infiltration, maxillary right first premolar infiltration, maxillary left first premolar infiltration, right inferior alveolar injection, left inferior alveolar injection, right long buccal infiltration (one-half cartridge) and left long buccal infiltration (one-half cartridge). They analyzed venous blood samples for articaine levels. They used noninvasive acoustic tonometry to measure a variety of cardiovascular parameters over a two-hour period.

Results. Plasma concentration curves of articaine over time were similar for both solutions, with peak concentrations and times to maximum concentration being 2,037 nanograms per milliliter and 22 minutes for A100 and 2,145 ng/mL and 22 minutes for A200. At the 10-minute point, the mean systolic blood pressure and heart rate were significantly elevated (P < .05) with A100 versus A200.

Conclusions. Maximum dose recommendations for the A100 solution also can be applied to the A200 solution. A200 produces less cardiovascular stimulation than does A100.

Clinical Implications. A200 is as safe as A100, and may be preferable to A100 in patients with cardiovascular disease and in those taking drugs that reportedly enhance the systemic effects of epinephrine.

Key Words: Dental local anesthetics; articaine; epinephrine; pharmacokinetics; blood pressure; cardiac output; arterial elasticity; arterial tonometer




This article has been cited by other articles:


Home page
 Br J AnaesthHome page
A. Szabo, N. Szentandrassy, P. Birinyi, B. Horvath, G. Szabo, T. Banyasz, I. Marton, P. P. Nanasi, and J. Magyar
Effects of articaine on action potential characteristics and the underlying ion currents in canine ventricular myocytes
Br. J. Anaesth., November 1, 2007; 99(5): 726 - 733.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright©1995-2006 American Dental Association (ADA).
Reproduction or republication strictly prohibited without prior written permission of ADA.